Cancer Family
Solid Neoplasm
CI-CAN-00000052Explore in graph →
Non-malignant1,822 active trials28 evidence items
- NCIt
- C9292
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000052Explore in graph →
Clinical trials
6,088 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04504942 | Basket Study of Leronlimab (PRO 140) in Patients With CCR5+ Locally Advanced or Metastatic Solid Tumors | completed | Phase 2 | 16 | CytoDyn, Inc.INDUSTRY | 1 | Jan 23, 2026 | clinicaltrials |
| NCT04627740 | Anti-ALPP CAR-T Cells Immunotherapy for Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 5 | Xinqiao Hospital of ChongqingOTHER | 1 | Jan 20, 2026 | clinicaltrials |
| NCT06553157 |
| Statins Effect on Incidence of Side Effects of Platinum Based Chemotherapy |
| completed |
| Phase 1 / Phase 2 |
| 56 |
| Minia UniversityOTHER |
| 1 |
| Jan 20, 2026 |
| clinicaltrials |
| NCT06556108 | ALPP CAR-T Cells for ALPP-Positive Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 5 | Xinqiao Hospital of ChongqingOTHER | 1 | Jan 20, 2026 | clinicaltrials |
| NCT05388058 | Topical Cannabidiol for the Treatment of Chemotherapy-Induced Peripheral Neuropathy | completed | Phase 2 | 40 | Mayo ClinicOTHER | 1 | Jan 16, 2026 | clinicaltrials |
| NCT05276284 | Thiopurine Enhanced Mutations for PD-1/Ligand-1 Efficacy(TEMPLE) | completed | Phase 1 / Phase 2 | 18 | Kristoffer RohrbergOTHER | 1 | Jan 14, 2026 | clinicaltrials |
| NCT02264613 | ALRN-6924 in Patients With Advanced Solid Tumors or Lymphomas | completed | Phase 1 / Phase 2 | 142 | Aileron Therapeutics, Inc.INDUSTRY | 1 | Jan 13, 2026 | clinicaltrials |
| NCT04773782 | A Study of Avapritinib in Pediatric Patients With Solid Tumors Dependent on KIT or PDGFRA Signaling | completed | Phase 1 / Phase 2 | 29 | Blueprint Medicines CorporationINDUSTRY | 9 | Jan 13, 2026 | clinicaltrials |
| NCT05002270 | JAB-21822 Activity in Adult Patients With Advanced Solid Tumors Harboring KRAS G12C Mutation | completed | Phase 1 / Phase 2 | 29 | Jacobio Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Jan 13, 2026 | clinicaltrials |
| NCT04175847 | A Phase I /IIa Study of RC88-ADC in Subjects With Advanced Malignant Solid Tumors | completed | Phase 1 / Phase 2 | 198 | RemeGen Co., Ltd.INDUSTRY | 1 | Jan 7, 2026 | clinicaltrials |
| NCT05174585 | JAB-BX102 Monotherapy and Combination With Pembrolizumab in Adult Patients With Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 21 | Jacobio Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Jan 6, 2026 | clinicaltrials |
| NCT05774873 | The Primary Objective of This Study to Evaluate the Safety and Tolerability of IBI334 and Determine the Maximum Tolerated Dose (MTD) and the Recommended Phase 2 Dose (RP2D)and Anti Tumor Activity of IBI334. | completed | Phase 1 / Phase 2 | 28 | Innovent Biologics (Suzhou) Co. Ltd.INDUSTRY | 1 | Jan 6, 2026 | clinicaltrials |
| NCT03993678 | Intratumoral Injection of IP-001 Following Thermal Ablation in Patients With Advanced Solid Tumors. | completed | Phase 1 / Phase 2 | 28 | Swiss Cancer InstituteOTHER | 1 | Dec 30, 2025 | clinicaltrials |
| NCT05508334 | A Study to Assess the Safety and Tolerability of RC88 for Patients With Advanced Solid Tumours | completed | Phase 1 / Phase 2 | 41 | RemeGen Co., Ltd.INDUSTRY | 1 | Dec 22, 2025 | clinicaltrials |
| NCT04349267 | Study of BMS-986315 Alone and in Combination With Nivolumab or Cetuximab in Participants With Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 44 | Bristol-Myers SquibbINDUSTRY | 3 | Dec 17, 2025 | clinicaltrials |
| NCT04021043 | BMS-986156, Ipilimumab, and Nivolumab With or Without Stereotactic Body Radiation Therapy in Treating Patients With Advanced or Metastatic Lung/Chest or Liver Cancers | completed | Phase 1 / Phase 2 | 51 | M.D. Anderson Cancer CenterOTHER | 1 | Dec 3, 2025 | clinicaltrials |
| NCT05134948 | A Study to Assess Relatlimab and Nivolumab Fixed-dose Combination in Chinese Participants With Advanced Solid Tumors(RELATIVITY 059) | completed | Phase 1 / Phase 2 | 24 | Bristol-Myers SquibbINDUSTRY | 1 | Dec 3, 2025 | clinicaltrials |
| NCT05383482 | Afuresertib +Sintilimab+Chemotherapy in Patients With Selected Solid Tumors That Resistance to Prior Anti-PD-1/PD-L1 | completed | Phase 1 / Phase 2 | 22 | Laekna LimitedINDUSTRY | 1 | Nov 17, 2025 | clinicaltrials |
| NCT03911557 | Durvalumab and Tremelimumab Combination in Somatically Hypermutated Recurrent Solid Tumors | completed | Phase 2 | 14 | John L. Villano, MD, PhDOTHER | 1 | Nov 12, 2025 | clinicaltrials |
| NCT04819373 | BDB001-201: A Clinical Study of BDB001 in Patients With PD-(L)1 Refractory Solid Tumors | completed | Phase 2 | 1 | Eikon TherapeuticsINDUSTRY | 1 | Nov 12, 2025 | clinicaltrials |
| NCT05847686 | Psilocybin-Assisted Therapy for the Treatment of Cancer-Related Anxiety in Patients With Metastatic Cancer | completed | Phase 1 / Phase 2 | 55 | University of WashingtonOTHER | 1 | Nov 5, 2025 | clinicaltrials |
| NCT02875548 | A Study to Assess Long-term Safety of Tazemetostat in Adult Participants of All Ages With Any Disease Treated With Tazemetostat in a Previous Clinical Study(TRuST) | completed | Phase 1 / Phase 2 | 58 | Epizyme, Inc.INDUSTRY | 7 | Nov 4, 2025 | clinicaltrials |
| NCT05597839 | Study of DF9001 in Patients With Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 24 | Dragonfly TherapeuticsINDUSTRY | 1 | Oct 29, 2025 | clinicaltrials |
| NCT04497116 | Study of RP-3500, Camonsertib, in Advanced Solid Tumors(TRESR) | completed | Phase 1 / Phase 2 | 276 | Repare TherapeuticsINDUSTRY | 4 | Oct 21, 2025 | clinicaltrials |
| NCT03493945 | Phase I/II Study of Immunotherapy Combination BN-Brachyury Vaccine, M7824, N-803 and Epacadostat (QuEST1) | completed | Phase 1 / Phase 2 | 59 | National Cancer Institute (NCI)NIH | 1 | Sep 30, 2025 | clinicaltrials |
| NCT03195478 | A Study of Nivolumab in Combination With Ipilimumab in Chinese Participants With Previously Treated Advanced or Recurrent Solid Tumors | completed | Phase 1 / Phase 2 | 37 | Bristol-Myers SquibbINDUSTRY | 1 | Sep 15, 2025 | clinicaltrials |
| NCT05161390 | Study of LM-302 in Patients With Advance Solid Tumors | completed | Phase 1 / Phase 2 | 153 | LaNova Medicines Zhejiang Co., Ltd.INDUSTRY | 1 | Sep 12, 2025 | clinicaltrials |
| NCT05199753 | Study of LM-108 as a Single Agent or in Combination With Anti-PD-1 Antibody in Subjects With Advanced Solid Tumours | completed | Phase 1 / Phase 2 | 78 | LaNova Australia Pty LimitedINDUSTRY | 1 | Sep 12, 2025 | clinicaltrials |
| NCT00712712 | Morphine After Radiofrequency Ablation of Painful Bone Metastases in Patients With Cancer(MEDOR) | completed | Phase 2 | 78 | Institut BergoniéOTHER | 1 | Aug 29, 2025 | clinicaltrials |
| NCT04564027 | A Study Investigating DNA-damage Response Agents in Molecularly Altered Advanced Cancer | completed | Phase 2 | 54 | AstraZenecaINDUSTRY | 3 | Aug 29, 2025 | clinicaltrials |
| NCT03977467 | Atezolizumab and Tiragolumab in Patients With NSCLC or Advanced Solid Tumors Having Had Prior Treatment With a PD-1 Inhibitor | completed | Phase 2 | 46 | SCRI Development Innovations, LLCOTHER | 1 | Aug 27, 2025 | clinicaltrials |
| NCT05578872 | A Study of ANV419 Alone or in Combination With Approved Treatment in Patients With Cutaneous Melanoma (OMNIA-1). | completed | Phase 1 / Phase 2 | 29 | Anaveon AGINDUSTRY | 5 | Aug 26, 2025 | clinicaltrials |
| NCT05014828 | To Evaluate the Efficacy and Safety of Tislelizumab in Combination With Lenvatinib in Participants With Selected Solid Tumors | completed | Phase 2 | 58 | BeiGeneINDUSTRY | 1 | Aug 24, 2025 | clinicaltrials |
| NCT03314935 | A Phase 1/2 Study of INCB001158 in Combination With Chemotherapy in Subjects With Solid Tumors | completed | Phase 1 / Phase 2 | 149 | Incyte CorporationINDUSTRY | 3 | Aug 12, 2025 | clinicaltrials |
| NCT02428712 | A Study of FORE8394 as a Single Agent in Patients With Advanced Unresectable Solid Tumors | completed | Phase 1 / Phase 2 | 113 | Fore BiotherapeuticsINDUSTRY | 1 | Jul 29, 2025 | clinicaltrials |
| NCT02611024 | Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors | completed | Phase 1 / Phase 2 | 316 | PharmaMarINDUSTRY | 6 | Jul 9, 2025 | clinicaltrials |
| NCT03520075 | Study of ASTX029 in Subjects With Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 192 | Taiho Oncology, Inc.INDUSTRY | 4 | Jul 3, 2025 | clinicaltrials |
| NCT00540982 | Vinorelbine in Treating Patients With Advanced Solid Tumors That Have Not Responded to Treatment and Liver Dysfunction | completed | Phase 1 / Phase 2 | 47 | City of Hope Medical CenterOTHER | 1 | Jul 2, 2025 | clinicaltrials |
| NCT01197885 | Efficacy and Safety Study of Multiple Doses of IMAB362 in Patients With Advanced Gastroesophageal Cancer | completed | Phase 2 | 54 | Ganymed Pharmaceuticals GmbHINDUSTRY | 5 | Jun 13, 2025 | clinicaltrials |
| NCT05253053 | To Evaluate Efficacy and Safety of TT-00420 (Tinengotinib) as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 84 | TransThera Sciences (Nanjing), Inc.INDUSTRY | 1 | Jun 12, 2025 | clinicaltrials |
| NCT04393298 | A Study to Assess the Safety, Pharmacokinetics and Anti Tumor Activity of UCB6114 Administered Intravenously to Participants With Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 93 | UCB Biopharma SRLINDUSTRY | 2 | May 29, 2025 | clinicaltrials |
| NCT06208124 | A Study of IMM-6-415 in RAS/RAF Mutant Solid Tumors | completed | Phase 1 / Phase 2 | 30 | Immuneering CorporationINDUSTRY | 1 | May 28, 2025 | clinicaltrials |
| NCT02799095 | A Study of the Effects of ALKS 4230 (Nemvaleukin Alfa) on Subjects With Solid Tumors | completed | Phase 1 / Phase 2 | 243 | Mural Oncology, IncINDUSTRY | 7 | May 21, 2025 | clinicaltrials |
| NCT04555837 | Alisertib and Pembrolizumab for the Treatment of Patients With Rb-deficient Head and Neck Squamous Cell Cancer | completed | Phase 1 / Phase 2 | 24 | M.D. Anderson Cancer CenterOTHER | 1 | May 20, 2025 | clinicaltrials |
| NCT04914286 | A Study of GFH018 in Combination With Toripalimab in Patients With Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 148 | Genfleet Therapeutics (Shanghai) Inc.INDUSTRY | 2 | May 14, 2025 | clinicaltrials |
| NCT04082572 | Pembrolizumab Before Surgery for the Treatment of Mismatch Repair Deficient Locally Advanced Solid Cancers | completed | Phase 2 | 35 | M.D. Anderson Cancer CenterOTHER | 1 | May 13, 2025 | clinicaltrials |
| NCT04383938 | Phase 1/2 Study of APR-246 in Combination With Pembrolizumab in Subjects With Solid Tumor Malignancies | completed | Phase 1 / Phase 2 | 40 | Aprea TherapeuticsINDUSTRY | 1 | May 13, 2025 | clinicaltrials |
| NCT03570619 | Immunotherapy in Patients With Metastatic Cancers and CDK12 Mutations(IMPACT) | completed | Phase 2 | 56 | University of Michigan Rogel Cancer CenterOTHER | 1 | May 8, 2025 | clinicaltrials |
| NCT02632448 | A Study of LY2880070 in Participants With Advanced or Metastatic Cancer | completed | Phase 1 / Phase 2 | 229 | Esperas Pharma Inc.OTHER | 4 | May 2, 2025 | clinicaltrials |
| NCT02717507 | Carvedilol in Preventing Heart Failure in Childhood Cancer Survivors | completed | Phase 2 | 196 | Children's Oncology GroupNETWORK | 4 | Apr 23, 2025 | clinicaltrials |
Data updated 22 days agoSource updated Jan 23, 2026source: clinicaltrials